Drug
Dasiglucagon clinical trials
Also written ZP4207.
How studies write it
Studies that test it under each name
Studies by the year they started
22 studies that test it; most in 2019 (5)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 2 |
| 2023 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 6
Zealand Pharma (15) · Steno Diabetes Center Copenhagen (2) · Filip Krag Knop (1) · University Hospital, Gentofte, Copenhagen (1) · Massachusetts General Hospital (1) · Inreda Diabetic B.V. (1) · Insel Gruppe AG, University Hospital Bern (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses dasiglucagon is read from its arms, and is right about nine times in ten.
Testing it · 22
- Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital HyperinsulinismCompletedPhase 3Zealand PharmaNCT03941236Written as dasiglucagon
- A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1DCompletedPhase 3Zealand PharmaNCT05378672Written as Dasiglucagon
- Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital HyperinsulinismCompletedPhase 2/3Zealand PharmaNCT04172441Written as dasiglucagon
- A Stable Glucagon Analog Administered by a Bihormonal Closed Loop SystemWithdrawnPhase 2Inreda Diabetic B.V.NCT05454709Written as Dasiglucagon
- A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital HyperinsulinismCompletedPhase 3Zealand PharmaNCT03777176Written as Dasiglucagon
- Micro Glucagon During Exercise in Type 1 DiabetesWithdrawnEarly Phase 1Insel Gruppe AG, University Hospital BernNCT04192019Written as Micro-glucagon
- A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DMCompletedPhase 3Zealand PharmaNCT03895697Written as dasiglucagon
- Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated AdultsWithdrawnPhase 2Zealand PharmaNCT04824872Written as Dasiglucagon
- Treatment of Post-bariatric HypoglycaemiaCompletedPhase 2Filip Krag KnopNCT04836273Written as Dasiglucagon
- Pen-Administered Low-Dose Dasiglucagon for Prevention and Treatment of Hypoglycemia in People With Type 1 DiabetesCompletedPhase 2Steno Diabetes Center CopenhagenNCT04764968Written as Dasiglucagon
- Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM ChildrenCompletedPhase 3Zealand PharmaNCT03667053Written as dasiglucagon
- A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes SubjectsCompletedPhase 3Zealand PharmaNCT03378635Written as Dasiglucagon
- Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DMCompletedPhase 3Zealand PharmaNCT03688711Written as Dasiglucagon
- A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes MellitusCompletedPhase 3Zealand PharmaNCT03216226Written as dasiglucagon
- Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV AdministrationCompletedPhase 1Zealand PharmaNCT03735225Written as Dasiglucagon
- Low-dose Dasiglucagon for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 DiabetesCompletedPhase 2Steno Diabetes Center CopenhagenNCT04449692Written as Dasiglucagon
- Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric BypassCompletedPhase 2University Hospital, Gentofte, CopenhagenNCT03984370Written as ZP4207
- The Bihormonal iLet Bionic Pancreas Feasibility StudyCompletedPhase 2/3Massachusetts General HospitalNCT03840278Written as Dasiglucagon
- ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed GlucagonCompletedPhase 2Zealand PharmaNCT02916251Written as ZP4207(dasiglucagon) glucagon analogue
- Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed GlucagonCompletedPhase 2Zealand PharmaNCT02660008Written as ZP4207
See all 22 studies that test dasiglucagon →
Given in every arm · 2 — dasiglucagon is usual care beside what is tested
- Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese AdolescentsCompletedPhase 1Novo Nordisk A/SNCT06588504Written as Dasiglucagon
- Feasibility Trial Testing the Bionic Pancreas With ZP4207CompletedPhase 2Zealand PharmaNCT02971228Written as ZP4207 (dasiglucagon)
Codes
What other systems call dasiglucagon · ClinicalTrials.gg INT001418
- MeSH (NLM) C000710373dasiglucagonOne source NLM
- UNII (FDA) AD4J2O47FQDASIGLUCAGONConfirmed FDA, NLM, Wikidata
- RxNorm 2535233One source FDA
- Wikidata Q106158304dasiglucagonConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171918DasiglucagonOne source FDA
- DrugBank DB15226One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000710373 | dasiglucagon | One source NLM |
| UNII (FDA) | AD4J2O47FQ | DASIGLUCAGON | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2535233 | — | One source FDA |
| Wikidata | Q106158304 | dasiglucagon | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171918 | Dasiglucagon | One source FDA |
| DrugBank | DB15226 | — | One source Wikidata |
Also registered as dasiglucagon hydrochloride (UNII YQX12245A9 · RxNorm 2535234).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.